FDA Determines Regulatory Review Period for ADBRY Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for ADBRY, a human biological product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).